小分子酪氨酸激酶抑制剂伊马替尼的出现,彻底改变了慢性髓系白血病(CML)的疾病进程,将威胁生命的恶性肿瘤变成了可以用药物控制的慢性疾病。而第二代专门针对CML病因设计的TKI尼洛替尼的诞生,可以更强效、更精准地抑制Bcr-Abl,克服33种耐药突变中的32种,帮助那些对格列卫耐药的CML The advent of imatinib, a small-molecule tyrosine kinase inhibitor, has revolutionized the disease process of chronic myeloid leukemia (CML) and turned life-threatening malignancies into drug-controlled chronic diseases. The second generation of specially formulated TKI Nilotinib for the etiology of CML was able to inhibit Bcr-Abl more potently and more accurately, overcoming 32 of the 33 drug-resistant mutations and helping those resistant to Gleevec CML